Can bispecifics succeed where ADCs have failed?

Finessing oncology targets can be both tricky and challenging. Does changing the modality help?

November 23, 2021

Lessons learned from SITC – Part 1

Sometimes we learn more from failure than we do from success

November 16, 2021

New trials and tribulations in drugging KRAS mutations

A number of new developments to consider in the KRAS niche

November 12, 2021

An immunotherapy for the long run – or tail

With SITC fast coming up this week, immunotherapies in all sorts of shapes and guises are very much…

November 8, 2021

Scores on the doors in the TIGIT niche

Update on the various runners and riders in the TIGIT niche

November 3, 2021

A review of the emerging bispecific landscape

A look at the sheer breadth and depth of bispecific approaches from a myriad of different biotechs

October 27, 2021
Washington DC in Fall

SITC21 – What to Watch out for

SITC 2021 Preview

October 22, 2021